The purpose of this trial is to evaluate the safety and tolerability of multiple (3) intradermal doses of RXI-109 at small surgical incisions in the abdominal skin of healthy volunteers. The effect of RXI-109 versus placebo on scarring at these incision sites will be evaluated visually, histologically, and by biomarker analysis.

Inclusion Criteria:

• Males and females, 21-50 years of age
• General good health; if female not pregnant or lactating
• Phototype 3 and above based on the Fitzpatrick scale.

Exclusion Criteria:

• Pregnant or lactating
• Use of tobacco or nicotine-containing products within 1 month prior to enrollment and while on study
• Type 1 or 2 diabetes mellitus
• A history or presence of any medical condition or therapy that would make the subject an unsafe candidate in the opinion of the investigator